2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4212 Umbilical cord blood transplantation in pediatric germline predisposition syndromes

yang wan, Xia Chen2, Xiaolan Li3, Lipeng Liu4, Xiaoyan Zhang5, Yuanyuan Ren6, Aoli Zhang, MD7, Lixian Chang, MD8, Ye Guo9, Wenyu Yang10, Xiaofan Zhu, MD11, Fang Liu12
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background
Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative approach for pediatric patients with inherited germline predisposition syndromes. Umbilical cord blood transplantation (UCBT) is associated with a lower risk of graft-versus-host disease (GVHD) in the leukemia setting, although its efficacy and safety profile in patients with inherited germline predisposition syndromes remain less well defined.

Methods
This retrospective analysis included 44 consecutive HSCT procedures performed in 42 pediatric patients (median age 8.5 years, range 1–17) with IBMFS and related disorders, transplanted at a single center between 2018 and 2026. Diagnoses comprised Fanconi anemia (n=5), dyskeratosis congenita (n=4), GATA2 deficiency (n=8), Shwachman-Diamond syndrome (n=3), congenital amegakaryocytic thrombocytopenia (n=4), severe congenital neutropenia (n=2), CEBPA germline AML (n=2), Diamond-Blackfan anemia (n=2), and other conditions (n=12). Donor sources included matched sibling donor (MSD, n=13), haploidentical (HAPLO, n=13), and UCBT (n=18). Conditioning was classified as myeloablative (MAC, TCI ≥4, n=23) or reduced-intensity (RIC, TCI <4, n=19). Survival was estimated using the Kaplan-Meier method with log-rank tests; cumulative incidence of engraftment was assessed with competing risks analysis; and categorical comparisons were performed using Fisher's exact test.

Results
The overall neutrophil engraftment rate was 95.2% (40/42 evaluable), with a median time to engraftment of 13 days (IQR 11–16); median platelet engraftment occurred at 20 days (IQR 13–30). Two primary graft failures were observed, both occurring in the RIC-UCBT subgroup (2/5, 40%), whereas no failures were noted in the MAC-UCBT subgroup (0/13) or in other donor types (P=0.02). Grade II–IV acute GVHD developed in 7 of 42 patients (16.7%): MSD 1/13 (7.7%), HAPLO 4/13 (30.8%), and UCBT 2/18 (11.1%) (P=0.04 for HAPLO vs. others). Within the MAC subgroup (n=23), UCBT (n=13) achieved neutrophil engraftment comparable to HAPLO (median 15 vs. 13 days, P=0.31) and MSD (11 days, P=0.08), with no graft failures and a GVHD rate of 15.4% (2/13). In the RIC subgroup (n=19), UCBT (n=5) demonstrated the lowest GVHD rate (0%) but was associated with a 40% graft failure rate, whereas MSD (n=8) and HAPLO (n=6) had no failures. At a median follow-up of 21 months (range 0.5–94) among survivors, the 3-year overall survival was 92.9% (95% CI 85.1–100%), with no significant difference by donor type (MSD 92.3%, HAPLO 92.3%, UCBT 94.4%, P=0.88). Three deaths occurred: one patient with SDS due to CNS infection after second HSCT, one with DC due to severe GVHD after second HSCT, and one with DBA due to TA-TMA after MSD HSCT.

Conclusions
UCBT provides a consistent GVHD-sparing effect across conditioning intensities; however, the elevated graft failure rate observed in the RIC setting warrants caution. MAC effectively eliminates this engraftment risk while preserving UCBT's favorable low-GVHD profile, supporting the use of myeloablative conditioning for UCBT in this patient population.

yang wan: No relevant conflicts of interest to declare.